Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Persumac is an Iranian traditional herbal remedy composed of a powdered mixture of sumac (Rhus coriaria) and Bunium persicum (also known as black cumin or black zira). It has been studied for its potential anti-emetic effects, particularly in the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients. Clinical trials suggest that Persumac may reduce both the number and severity of nausea and vomiting episodes in patients with refractory CINV. The mechanism is not fully elucidated but is presumed to involve anti-inflammatory, antioxidant, or gastrointestinal-modulating properties attributed to its plant-based components[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Persumac.